Sun Pharmaceutical Industries share news, announcements and annual reports
NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap
Sun Pharmaceutical Industries Limited · Formerly Sun Pharmaceuticals Industries · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1994 on BSE, Feb 1995 on NSE
Last close ₹1,770.00down ₹7.70 (0.43%)BSE ₹1,768.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,777.70.
2 Nov: open ₹1,770.00, high ₹1,776.20, low ₹1,722.00
52-week range of traded prices to 2 Nov 2026
₹1,583.70Low, 29 Jan 2026₹2,046.90High, 31 Jul 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,24,682 Cr13th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.73
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 32.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.76
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.90%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.1%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 15.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 34,57,79149.8% delivered
Sun Pharmaceutical Industries share news and announcements
1,454 announcements, routine notices left out, newest first. Page 15 of 30.
Sep 2018
11 Sep · Legal
Exchange has sought clarification from the Company with respect to news item captioned-Sun Pharma Mohali plant on FDA radar In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.7 Sep · News Verification
Exchange has sought clarification from Sun Pharmaceutical Industries Limited with respect to recent news item captioned "Sun Pharma falls 5% on report of co getting 6 observations by US FDA for Halol unit". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: Whether you / company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
Aug 2018
14 Aug · Results
13 Aug · Disclosure
Jul 2018
26 Jul · Board meeting
12 Jul · Legal
Exchange has sought clarification from Sun Pharmaceutical Industries Limited with respect to announcement dated 11-Jul-2018, regarding " Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated July 11, 2018, titled "DUSA Pharmaceuticals, Inc. files lawsuit against Biofrontera Inc. for patent infringement, trade secret misappropriation, and tortious interference".". On basis of above the Company is required to clarify following: 1. Quantum of claims, if any 2. Expected financial implications, if any, due to compensation, penalty etc; 3. Brief details of litigation viz. name(s) of the opposing party, court/ tribunal/agency where litigation is filed, brief details of dispute/litigation; The response of the Company is awaited.
Jun 2018
8 Jun · News Verification
Exchange has sought clarification from Sun Pharmaceutical Industries Limited with respect to recent news item captioned "No re-inspection at Sun Pharma's Halol unit sends stock soaring 9%". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
May 2018
25 May · Results
25 May · Board meeting
24 May · Disclosure
Apr 2018
Mar 2018
Feb 2018
23 Feb · Updates
14 Feb · Disclosure